BioSpace News Archive

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce that the European Commission has granted the Conditional Marketing Authorization for their lead compound HEPCLUDEX®.

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect.

Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a decline of 14.9%, due primarily to demand impacts related to COVID-19 and competitive and payer pressures on certain products

Aurinia Pharmaceuticals Inc. announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Saqib Islam, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 10:20 a.m. Eastern Standard Time.

CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testing

Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020.

Isofol Medical AB, announced that the CEO Ulf Jungnelius has chosen to make full use of the opportunity to subscribe for all warrants in the incentive program for the CEO - The Warrant Program 2020.

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended June 30, 2020 on Thursday, August 6th, 2020.